Metformin linked to lower risk of head, neck cancer

Metformin linked to lower risk of head, neck cancer

(HealthDay)—Metformin is associated with a lower risk of developing head and neck cancer in patients with diabetes, according to a study published in the September issue of Head & Neck.

Yung-Chang Yen, M.D., Ph.D., from the Chi Mei Medical Centre in Tainan City, Taiwan, and colleagues compared the risk of and in 2011 among 66,600 patients, all newly diagnosed with in 2002. Metformin was subsequently taken by half of the patients. The two groups were matched for comorbidities, sex, and age.

The researchers found that the incidence of head and neck cancer was 34 percent lower in the metformin group than in the control group (adjusted hazard ratio [HR], 0.66). Similarly, among those taking metformin, the risks for oropharyngeal cancer (adjusted HR, 0.66) and nasopharyngeal carcinoma (adjusted HR, 0.5) were significantly lower.

"These findings indicate the potential clinical benefits of using metformin to prevent patients with diabetes from developing head and neck cancer," the authors write.


Explore further

Metformin use associated with less CRC risk in US population

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2015 HealthDay. All rights reserved.

Citation: Metformin linked to lower risk of head, neck cancer (2015, September 9) retrieved 11 November 2019 from https://medicalxpress.com/news/2015-09-metformin-linked-neck-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
27 shares

Feedback to editors

User comments